– seuraa lopun ajan aiheita

WHO-diktatuuri tartuntatautilainsäädäntöön?

Nato-avusteinen rokotepakko, rokotepassi, maskipakko ja WHO-diktatuuri pysyvästi tartuntatautilainsäädäntöön?

Artikkeliin liittyvä kuyva

Sosiaali- ja terveysministeriö (STM) pyytää lausuntoja covid-19-epidemian aikana laatimaansa muistioon tartuntatautilain muutos- ja kehittämistarpeista ”laajan uudistuksen toimeenpanon tueksi” 17.3.2023 klo 16.15 mennessä. STM:n muistiossa ehdotetaan pysyviksi muutoksiksi tartuntatautilakiin muun muassa Nato-yhteistyötä pandemioiden aikana, Puolustusvoimien virka-avun helpottamistatartuntatautien torjunnassa”, pakollista covid-19-injektiota (48 §), koronapassin kaltaisen välineen käyttöä, viranomaisten mahdollisuutta edellyttää kasvomaskia sekä ristiriidatonta lainsäädäntöä kansainvälisen terveyssäännöstön (IHR) ja muun kansainvälisen lainsäädännön kanssa.

MKR:n näkemys STM:n ehdottamiin tartuntatautilain muutoksiin tiivistetysti

Jäsenvaltioidensa rahoittama Maailman terveysjärjestö (WHO) on muuttunut viimeisten vuosikymmenien aikana yhä enemmän yksityisten toimijoiden – erityisesti Bill & Melinda Gates -säätiön – rahoittamaksi. Kyseinen säätiö rahoittaa jopa viidenneksen WHO:n kokonaisbudjetista.

Koska säätiöllä on eturistiriitoja kattavista sijoituksistaan lääketeollisuuteen, on WHO:n päätöksiin – kuten influenssapandemian määritelmän muutokseen, kansainväliseen terveyssäännöstöön (IHR) sekä pandemiasopimukseen – suhtauduttava suurella varauksella. Suomen ei tule seurata sokeasti ei-demokraattisesti valittujen organisaatioiden vaikutusvallan alaisuudessa toimivaa WHO:ta, eikä sen linjauksia kyseenalaistamatta noudattavaa Euroopan unionia.

Seuraavan pandemian syntyessä Suomen tulee arvioida taudin vaarallisuus itsenäisesti, eikä turvautua kansainvälisiin toimijoihin, jotka ovat alttiita monikansallisten suuryritysten intresseille. Suomen kansantalouden ja -terveyden kannalta ei ole järkevää turvautua ihmisten perusoikeuksia rajoittaviin, tehottomiin, haitallisiin ja kalliisiin sulkutoimiin epidemian aikana.

Korkeatasoisin tutkimusnäyttö eli satunnaiskontrolloituja tutkimuksia kokoavat meta-analyysit ja kirjallisuuskatsaukset osoittavat, että kasvomaskit eivät suojaa hengitystieviruksen aiheuttamilta tartunnoilta. On myös käynyt useilla tavoilla selväksi, että covid-injektiot eivät ole tehokkaita eivätkä turvallisia. Kasvomaskien ja covid-injektioiden mainitseminen tartuntatautilaissa ei ole tieteellisesti, tilastollisesti eikä eettisesti perusteltua.

Sen sijaan Suomen edun mukaista on hyödyntää laajasti olemassa olevia lääkkeitä, ravintoaineita, terveellistä ruokavaliota sekä mahdollisimman laajasti muita saatavilla olevia menetelmiä tartuntatautien ennaltaehkäisemiseksi ja sairastuneiden hoitamiseksi.

Lääketeollisuuden ja lääkeviranomaisten tulisi arvioida kriittisesti uusien lääkkeiden laatua, koska rokotteina markkinoitavien injektioiden osalta joudutaan turvautumaan uhkailuun ja pakottamiseen – tämä ei ole merkki luottamuksesta kyseisiä tuotteita ja valmistajia kohtaan.

Kansainvälinen terveyspolitiikka on pahoin korruptoitunut, ja korruption jäljet johtavat Yhdysvaltoihin, jonka johtamaan liittoumaan Suomikin määrätietoisesti pyrkii. Kansalaisten luottamuksen ovat menettäneet muun muassa WHO, Yhdysvaltain elintarvike- ja lääkevirasto (FDA), Yhdysvaltain tartuntatautivirasto (CDC), Yhdysvaltain terveysvirasto (NIH), Euroopan lääkevirasto (EMA) sekä Euroopan komissio.

Suomen ja suomalaisten tulee tunnustaa, että olimme väärässä luottaessamme kansainvälisiin auktoriteetteihin, suhtautua äärimmäisen kriittisesti kansainvälisten organisaatioiden sopimuksiin ja luottaa Suomen maailmallakin tunnustusta keränneeseen korkeatasoiseen osaamiseen – erityisesti terveysosaamiseen – eikä noudattaa orjallisesti monikansallisten suuryritysten etua ajavia globaaleja toimijoita. Emme tarvitse ulkopuolista ohjeistusta, vaan vapautta itsenäiseen päätöksentekoon.

Tartuntatautilakiin ei ole tarpeen tehdä muutoksia.

Lue MKR:n yli 100 laadukasta lähdettä sisältävä lausunto kokonaisuudessaan ja laadi oma lausuntosi 17.3.2023 klo 16.15 mennessä. Yhdessä voimme estää suunnitellun terveystyrannian!

Lausunnon voit antaa seuraavassa osoitteessa: https://www.lausuntopalvelu.fi/FI/Proposal/Participation?proposalId=cc751361-6b63-4419-a66b-fe4afde31bb9

Lausunto-Tartuntatautilaki Lataa

    Lähteet:

    1. Sosiaali- ja terveysministeriö. Muistio tartuntatautitoimijoiden ja viranomaisten esittämistä lainsäädännön kehittämistarpeista. https://www.lausuntopalvelu.fi/FI/Proposal/DownloadProposalAttachment?proposalId=cc751361-6b63-4419-a66b-fe4afde31bb9&attachmentId=20007
    2. World Health Organization. Our contributors. https://www.who.int/about/funding/contributors
    3. World Health Organization. Budget implementation summary. https://www.who.int/about/accountability/results/who-results-report-2020-mtr/budget-summary-details
    4. World Economic Forum. How is the World Health Organization funded? https://www.weforum.org/agenda/2020/04/who-funds-world-health-organization-un-coronavirus-pandemic-covid-trump/
    5. World Health Organization. 2007. Working for health. https://www.slideshare.net/WERI/working-for-health-2100594
    6. Vaughan, J. Mogedal, S. Kruse, S. Lee, K. Walt, G. de Wilde, K. Financing the World Health Organisation: global importance of extrabudgetary funds. Health Policy 1996, 35: 229-245. https://pubmed.ncbi.nlm.nih.gov/10157400/
    7. Politico. 2017. Meet the world’s most powerful doctor: Bill Gates. https://www.politico.eu/article/bill-gates-who-most-powerful-doctor/
    8. Gavi. The Bill & Melinda Gates Foundation. https://www.gavi.org/investing-gavi/funding/donor-profiles/bill-melinda-gates-foundation
    9. Bill & Melinda Gates Foundation. Committed grants. https://www.gatesfoundation.org/about/committed-grants?page=5&q=world%20health%20organization
    10. World Health Organization. Pandemic preparedness. 2009a. https://web.archive.org/web/20090503221306/http://www.who.int/csr/disease/influenza/pandemic/en/index.html
    11. World Health Organization. Pandemic preparedness. 2009b. https://web.archive.org/web/20090505221413/http://www.who.int/csr/disease/influenza/pandemic/en/index.html
    12. World Health Organization. Pandemic influenza. 2014. https://web.archive.org/web/20140925200628/https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/pandemic-influenza
    13. Yle. 2009. WHO julisti sikainfluenssan pandemiaksi. https://yle.fi/a/3-5266535
    14. Kelly, H. The classical definition of a pandemic is not elusive. Bulletin of the World Health Organization 2011, 89: 540-541. https://apps.who.int/iris/handle/10665/270942
    15. The Nation. Bill Gates’s charity paradox. https://www.thenation.com/article/society/bill-gates-foundation-philanthropy/
    16. Worldometer. World population. https://www.worldometers.info/world-population/
    17. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/
    18. Ikonen, N. Murtopuro, S. Haveri, A. Virtanen, M. Baum, U. Isoniemelä, V. Savolainen-Kopra, C. Nohynek, H. Lyytikäinen, O. Influenssakausi Suomessa, viikot 40/2017-20/2018. Terveyden ja hyvinvoinnin laitos. https://www.julkari.fi/bitstream/handle/10024/136791/URN_ISBN_978-952-343-159-1.pdf
    19. Tilastokeskus. Äidinkielenään kotimaisia kieliä puhuvien määrän väheneminen kiihtyi. https://www.stat.fi/til/vaerak/2017/vaerak_2017_2018-03-29_tie_001_fi.html
    20. Spreeuwenberg, P. Kroneman, M. Paget, J. Reassessing the global mortality burden of the 1918 influenza pandemic. American Journal of Epidemiology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314216/
    21. The Spanish flu (1918-20): the global impact of the largest influenza pandemic in history. https://ourworldindata.org/spanish-flu-largest-influenza-pandemic-in-history
    22. MKR. Covid-tilannekatsaus: mikä on totuus? https://mkrsuomi.fi/korona-tilannekatsaus/
    23. Sosiaali- ja terveysministeriö. 2012. Kansallinen varautumissuunnitelma influenssapandemiaa varten. https://julkaisut.valtioneuvosto.fi/bitstream/handle/10024/72870/Julk201209.pdf?sequence=1&isAllowed=y
    24. World Health Organization. Equatorial Guinea confirms first-ever Marburg virus disease outbreak. https://www.afro.who.int/countries/equatorial-guinea/news/equatorial-guinea-confirms-first-ever-marburg-virus-disease-outbreak
    25. Nayakarahuka, L. Kankya, C. Krontveit, R. Mayer, B. Mwiine F. Lutwama, J. Skjerve, E. How severe and prevalent are Ebola and Marburg viruses? A systematic review and meta-analysis of the case fatality rates and seroprevalence. BMC Infectious Diseases 2016, 16. https://bmcinfectdis.biomedcentral.com/counter/pdf/10.1186/s12879-016-2045-6.pdf
    26. Ajelli, M. Merler, S. Transmission potential and design of adequate control measures for Marburg hemorrhagic fever. PLoS One 2012, 7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519495/
    27. Centers for Disease Control and Prevention. History of MVD outbreaks. https://www.cdc.gov/vhf/marburg/outbreaks/chronology.html
    28. World Health Organization. Conceptual zero draft for the consideration of the intergovernmental negotiating body at its third meeting. https://apps.who.int/gb/inb/pdf_files/inb3/A_INB3_3-en.pdf
    29. World Health Organization. Article-by-article compilation of proposed amendments to the international health regulations (2005) submitted in accordance with decision WHA75(9) (2022). https://apps.who.int/gb/wgihr/pdf_files/wgihr2/A_WGIHR2_7-en.pdf
    30. CNBC. Bill Gates: My ’best investment’ turned $10 billion into $200 billion worth of economic benefit. https://www.cnbc.com/2019/01/23/bill-gates-turns-10-billion-into-200-billion-worth-of-economic-benefit.html
    31. Hoong, C. Huilin, K. Cho, S. Aravamudan, V. Are adequate vitamin D levels helpful in fighting COVID-19? A look at the evidence. Hormone and Metabolic Research 2020. https://vitamindwiki.com/tiki-download_wiki_attachment.php?attId=14334&page=Virtually%20no%20COVID-19%20cases%20in%20countries%20having%20more%20than%2030%20ng%20of%20Vitamin%20D%20-%20Sept%2017%2C%202020&download=y
    32. Ilie Petre, Stefanescu, Simina. Smith, Lee. 2020. The role of Vitamin D in the prevention of Coronavirus Disease 2019 infection and mortality. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202265/
    33. Martineau, A. Jolliffe, D. Hooper, R. Greenberg, L. Aloia, J. Bergman, P. Dubnov-Raz, G. Esposito, S. Ganmaa, D. Ginde, A. Goodall, E. Grant, C. Griffiths, C. Janssens, W. Laaksi, I. Manaseki-Holland, S. Mauger, D. Murdoch, D. Neale, R. Rees, J. Simpson, S. Stelmach, I. Kumar, G. Urashima, M. Camargo, C. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. British Medical Journal 2017, 1-14. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310969/
    34. Bergman, P. Lindh, Å. Björkhem-Bergman, L. Lindh, J. Vitamin D and respitatory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2013: 8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686844/
    35. Charan, J. Goval, J. Saxena, D. Yadav, P. Vitamin D for prevention of respiratory tract infections: A systematic review and meta-analysis. The Journal of Pharmacology & Pharmacotherapeutics 2012, 3: 300-303.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543548/
    36. Zittermann, A. Pilz, S. Hoffmann, H. März, W. Vitamin D and airway infections: a European perspective. European Journal of Medical Research 2016, 21. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806418/
    37. Jääskeläinen, T. Itkonen, S. Lundqvist, A. Erkkola, M. Koskela, T. Lakkala, K. Dowling, K. Hull, G. Kröger, H. Karppinen, J. Kyllönen, E. Härkänen, T. Cashman, K. Männistö, S. Lamberg-Allardt, C. The positivie impact of general vitamin D food fortification policy on vitamin D status in a representative adult Finnish population: evidence from an 11-y follow-up based on standardized 25-hydroxyvitamin D data. The American Journal of Clinical Nutrition 2017, 105: 1512-1520. https://www.semanticscholar.org/paper/The-positive-impact-of-general-vitamin-D-food-on-D-J%C3%A4%C3%A4skel%C3%A4inen-Itkonen/30fbb1e81a16b7a5a6c3376753060af5cac1c294
    38. Helldán, A. Raulio, S. Kosola, M. Tapanainen, H. Ovaskainen, M-L. Virtanen, S. Finravinto 2012 -tutkimus. 2013. https://www.julkari.fi/handle/10024/110839
    39. Spiro, A. Buttriss, J. Vitamin D: An overview of vitamin D status and intake in Europe. Nutrition Bulletin 2014, 39: 322-350. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288313/
    40. Shaifee, A. Athar, M. Gargari, O. Jafarabady, K. Siahvoshi, S. Mozhgani, S-H. Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients. https://link.springer.com/content/pdf/10.1186/s12985-022-01829-8.pdf
    41. Hill, A. Abdulamir, A. Ahmed, S. Asghar, A. Babalola, O. Basri, R. Chaccour, C. Chachar, A. Chowdhury, A. Elgazzar, A. Ellis, L. Falconer, J. Garratt, A. Hany, B. Hashim, H. Haque, W. Hayat, A. He, S. Jamshidian, R. Khan, W. Kirti, R. Krolewcki, A. Lanusse, C. Levi, J. Mahmud, R. Mangat, S. McCann, K. Mohan, A. Niaee, M. Okumus, N. Pilkington, V. Podder, C. Qavi, A. Raad, H. Razai, M. Sasank, S. Spoorthi, V. Surf, T. Wang, J. Wentzel, H. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. (Preprint) https://assets.researchsquare.com/files/rs-148845/v1_covered.pdf?c=1637584849
    42. Lawrie, T. Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance. https://b3d2650e-e929-4448-a527-4eeb59304c7f.filesusr.com/ugd/593c4f_8cb655bd21b1448ba6cf1f4c59f0d73d.pdf
    43. Argano, C. Bocchio, R. Natoli, G. Scibetta, S. Lo Monaco, M. Corrao, S. Protective effect of vitamin D supplementation on COVID-19-related intensive care hospitalization and mortality: Definitive evidence from meta-analysis and trial sequential analysis. https://www.mdpi.com/1424-8247/16/1/130
    44. Return of Private Foundation. 2022. Bill & Melinda Gates Foundation. https://docs.gatesfoundation.org/documents/2021%20bmgf%20form%20990-pf%20(pd%20copy).pdf
    45. Return of Private Foundation. 2016. Bill & Melinda Gates Foundation. https://docs.gatesfoundation.org/Documents/2016_BMGF_Form_990PF.pdf
    46. European Journalism Centre. About. https://www.ejc.net/about
    47. Project Syndicate. About us. https://www.project-syndicate.org/about
    48. CDC Foundation. CDC Foundation receives $13.5 million in grants for global health. https://www.cdcfoundation.org/blog-entry/cdc-foundation-receives-13.5-million-grant-from-gates-foundation
    49. Bill & Melinda Gates Foundation. Committed grants. https://www.gatesfoundation.org/about/committed-grants?page=3&q=national%20institutes%20of%20health&yearAwardedEnd=2020&yearAwardedStart=2020
    50. Extremely American – Worldwide. 2.1.2022. Vaccine hesistancy explained in a single VAERS pie chart: Deaths by vaccine type (1988-2021). https://www.extremelyamerican.com/post/vaccine-hesitancy-explained-in-a-single-vaers-pie-chart-deaths-by-vaccine-type-1988-2021
    51. Open VAERS. https://www.openvaers.com/vaersapp/reports.php
    52. National Vaccine Information Center. Search the VAERS database. https://www.medalerts.org/vaersdb/index.php
    53. Reuters. Wait what? FDA wants 55 years to process FOIA request over vaccine data. https://www.reuters.com/legal/government/wait-what-fda-wants-55-years-process-foia-request-over-vaccine-data-2021-11-18/
    54. World Health Organization. Global influenza programme – Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza. https://www.who.int/publications/i/item/non-pharmaceutical-public-health-measuresfor-mitigating-the-risk-and-impact-of-epidemic-and-pandemic-influenza
    55. Soltesz, K. Gustafsson, F. Timpka, T. Jaldén, J. Jidling, C. Heimerson, A. Schön, T. Spreco, A. Ekberg, J. Dahlström, Ö. Carlson, F. Jöud, A. Bernhardsson, B. The effect of interventions on COVID-19. Nature 588. https://www.nature.com/articles/s41586-020-3025-y
    56. Joffe, A. COVID-19: rethinking the lockdown groupthink. Frontiers of Public Health 2021, 9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952324/
    57. Bendavid, E. Oh, C. Bhattacharya, J. Ioannidis, A. Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19. European Journal of Clinical Investigation 2021, 51. https://onlinelibrary.wiley.com/doi/10.1111/eci.13484
    58. Pepp, K. Bjørnskov, C. Lockdown effects on Sars-CoV-2 transmission – The evidence from Northern Jutland. (Preprint) https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3756920
    59. Lundberg, J. Zeberg, H. Longitudinal variability in mortality predicts COVID-19 deaths. European Journal of Epidemiology 2021, 36. https://link.springer.com/article/10.1007/s10654-021-00777-x
    60. Gibron, J. Government mandated lockdowns do not reduce Covid-19 deaths: implications for evaluating the stringent New Zealand response. https://www.semanticscholar.org/paper/Government-mandated-lockdowns-do-not-reduce-deaths:-Gibson/ae33abae901371e353850df01657365fd128f741
    61. Larochelambert, Q. Marc, A. Antero, J. Bourg, E. Toussaint, J-F. Covid-19 mortality: A matter of vulnerability among nations facing limited margins of adaptation. Frontiers in Public Health 2020, 8. https://www.frontiersin.org/articles/10.3389/fpubh.2020.604339/full
    62. Letizia, A. Ramos, I. Obla, A. Goforth, C. Weir, D. Ge, Y. Bamrhan, M. Dutta, J. Ellis, E. Estrella, L. George, M-C. Gonzalez-Reiche, A. Graham, W. van de Guchte, A. Gutierres, R. Jones, F. Kalomoiri, A. Lizewski, R. Lizewski, S. Marayang, J. Marjanovic, N. Millar, E. Nair, V. Nudelman, G. Nunez, E. Pike, B. Porter, C. Regeimbal, J. Rirak, S. Santa Ana, E. Sealfon, R. Sebra, R. Simons, M. Soares-Schanoski, A. Sugiharto, V. Termini, M. Vangeti, S. Williams, C. Troyanskaya, O. van Bakel, H. Sealton, S. SARS-CoV-2 transmission among marine recruits during quarantine. The New England Journal of Medicine 2020, 383: 2407-2416. https://www.nejm.org/doi/full/10.1056/NEJMoa2029717
    63. Neil, T. McGorian, I. Hudson, N. Exploring inter-country coronavirus mortality. Panda. https://pandata.org/wp-content/uploads/2020/07/Exploring-inter-country-variation.pdf
    64. Forbes, H. Morton, C. Bacon, S. McDonald, H. Minassian, C. Brown, J. Rentsch, C. Mathur, R. Schulze, A. DeVito, N. MacKenna, B. Hulme, W. Croker, R. Walker, A. Williamson, E. Bates, C. Mehrkar, A. Curtis, H. Evans, D. Wing, K. Inglesby, B. Drysdale, H. Wong, A. Cockburn, J. McManus, R. Parry, J. Hester, F. Harper, S. Douglas, I. Smeeth, L. Evans, S. Bhaskaran, K. Eggo, R. Goldcre, B. Tomlinson, L. Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England. BMJ 2021, 372. https://www.bmj.com/content/372/bmj.n628
    65. Atkeson, A. Kopecky, K. Zha, T. Four stylized facts about COVID-19. National Bureau of Economic Research. https://www.nber.org/papers/w27719
    66. Bjørnskov, C. Did lockdown work? An economist’s cross-country comparison. https://www.semanticscholar.org/paper/Did-Lockdown-Work-An-Economist%E2%80%99s-Cross-Country-Bj%C3%B8rnskov/14c986d39e38969eb566da6f9d90c9f3b2203c1e
    67. Djaparidze, L. Lois, F. SARS-CoV-2 waves in Europe: A 2-stratum SEIRS model soution. (Preprint) https://www.medrxiv.org/content/10.1101/2020.10.09.20210146v1
    68. Herby, J. Jonung, L. Hanke, S. A literature review and meta-analysis of the effects of lockdowns on COVID-19 mortality. Johns Hopkins Institute for Applied Economics. https://sites.krieger.jhu.edu/iae/files/2022/01/A-Literature-Review-and-Meta-Analysis-of-the-Effects-of-Lockdowns-on-COVID-19-Mortality.pdf
    69. New York Post. 10 myths told by COVID experts – and now debunked. https://nypost.com/2023/02/27/10-myths-told-by-covid-experts-now-debunked/
    70. Petterson, S. Westfall, J. Miller, B. Projected deaths of despair from COVID-19. https://wellbeingtrust.org/wp-content/uploads/2020/05/WBT_Deaths-of-Despair_COVID-19-FINAL-FINAL.pdf
    71. Kailash Satyarthi Children’s Foundation. A study on impact of lockdown and economic disruption on poor rural households with special reference to children. https://www.researchcommonsonchildren.com/uploadfile/documents/A_Study_on_Impact_of_Lockdown_and_Economic_Disruption_on_Poor_Rural_Households.pdf
    72. Arena, P. Malta, M. Rimoin, A. Strathdee, S. Race, COVID-19 and deaths of despair. EClinical Medicine 2020, 25. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396816/
    73. Irish Cancer Society. Oireachtas Special Committee on COVID-19 Response. https://data.oireachtas.ie/ie/oireachtas/committee/dail/33/special_committee_on_covid_19_response/submissions/2020/2020-09-30_submission-averil-power-chief-executive-irish-cancer-society-scc19r-r-0419_en.pdf
    74. Singh, S. Roy, D. Sinha, K. Parveen, S. Sharma, G. Joshi, G. Impact of COVID-19 and lockdown on mental health of children and adolescents: A narrative review with recommendations. Psychiatry Research 2020, 293. https://www.sciencedirect.com/science/article/pii/S016517812031725X
    75. Miles, D. Stedman, M. Heald, A. Living with COVID-19: Balancing costs against benefits in the face of the virus. National Institute Economic Review 2020, 253. https://www.researchgate.net/publication/343278351_LIVING_with_COVID-19_BALANCING_COSTS_against_BENEFITS_in_the_FACE_of_the_VIRUS
    76. Rice, K. Wynne, B. Martin, V. Ackland, G. Effect of school closures on mortality from coronavirus disease 2019: Old and new predictions. BMJ Clinical Research 2020, 371. https://www.researchgate.net/publication/346031988_Effect_of_school_closures_on_mortality_from_coronavirus_disease_2019_Old_and_new_predictions
    77. Shlomai, A. Leshno, A. Sklan, E. Leshno, M. Modeling social distancing strategies to prevent SARS-CoV-2 spread in Israel – A cost-effectiveness analysis. Value in Health 2021, 24: 607-614. https://www.sciencedirect.com/science/article/pii/S1098301520344211
    78. Aragona, M. Barbato, A. Cavani, A. Costanzo, G. Mirisola, C. Public Health 2020, 186: 52-56. https://www.sciencedirect.com/science/article/pii/S0033350620302936
    79. Melnick, E. Ioannidis, J. Should governments continue lockdown to slow the spread of covid-19? BMJ 2020, 369. https://www.bmj.com/content/bmj/369/bmj.m1924.full.pdf
    80. Xiao, J. Shiu, E. Gao, H. Wong, J. Fong, M. Ryu, S. Cowling, B. Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings – personal protective and environmental measures. 2020. https://wwwnc.cdc.gov/eid/article/26/5/19-0994_article
    81. Jefferson, T. Jones, M. Al-Ansary, L. Bawazeer, G. Beller, E. Clark, J. Conly, J. Del Mar, C. Dooley, E. Ferroni, E. Glasziou, P. Hoffmann, T. Thorning, S. van Driel, M. Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1 – Face masks, eye protection and person distancing: systematic review and meta-analysis. (Preprint) https://www.medrxiv.org/content/10.1101/2020.03.30.20047217v2
    82. Offeddu, V. Yung, C. Low, M. Tam, C. Effectiveness of Masks and Respirators Against Respiratory Infections in Healthcare Workers: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases 2017, 65: 1934-1942. https://doi.org/10.1093/cid/cix681
    83. bin-Reza, F. Chavarrias, V. Nicoli, A. Chamberland, M. The use of masks and respirators to prevent transmission of influenza: a systematic review of the scientific evidence. Influenza and Other Respiratory Viruses 2012, 6: 257-267. https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1750-2659.2011.00307.x
    84. Brainard, J. Jones, N. Lake, I. Hooper, L. Hunter, P. Facemasks and similar barriers to prevent respiratory illness such as COVID-19: A rapid systematic review. medRxiv 2020. (Preprint) https://www.medrxiv.org/content/10.1101/2020.04.01.20049528v1
    85. Jefferson, T. Dooley, L. Ferroni, E. Al-Ansary, L. van Driel, M. Bawazeer, G. Jones, M. Hoffmann, T. Clark, J. Beller, E. Glasziou, P. Conly, J. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews 2023. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006207.pub6/full
    86. Kao, T. Huang, K-C. Huang, Y-L. Tsai, T-J. The physiological impact of wearing an N95 mask during hemodialysis as a precaution against SARS in patients with end-stage renal disease. Journal of the Formosan Medical Association 2004, 103: 624-628. https://www.researchgate.net/publication/8371248_The_physiological_impact_of_wearing_an_N95_mask_during_hemodialysis_as_a_precaution_against_SARS_in_patients_with_end-stage_renal_disease
    87. Beder, A. Büyükkocak, U. Sabuncuoglu, H. Keskil, Z. Keskil, S. Preliminary report on surgical mask deoxygenation during marjor surgery. Neurocirugia 2008, 19: 121-126. https://scielo.isciii.es/pdf/neuro/v19n2/3.pdf
    88. Person, E. Lemercier, C. Royer, A. Reychler, G. Effect of a surgical mask on six minute walking distance. Revue des maladies respiratoires 2018, 35: 264-268. https://pubmed.ncbi.nlm.nih.gov/29395560/
    89. Chughtai, A. Stelzer-Braid, S. Rawlinson, W. Pontivivo, G. Wang, Q. Pan, Y. Zhang, D. Zhang, Y. Li, L. Macintyre, R. BMC Infectious Diseases 2019, 19. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-4109-x
    90. Schwarz, S. Jenetzky, E. Krafft, H. Maurer, T. Martin, D. Corona child studies ”Co-Ki”: first results of a Germany-wide register on mouth and nose covering (mask) in children. Monatsschrift Kinderheilkunde 2021, 169: 353-365. https://pubmed.ncbi.nlm.nih.gov/33642617/
    91. Food and Drug Administration. What is gene therapy? https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy
    92. Food and Drug Administration. Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products. https://www.fda.gov/media/89036/download
    93. Il Tempo. Covid, Pfizer ammette: ”Non abbiamo testato il vaccino per fermare la trasmissione del virus”. https://www.iltempo.it/esteri/2022/10/11/news/covid-pfizer-janine-small-parlamento-ue-ammette-non-abbiamo-testato-vaccino-fermare-trasmissione-virus-33420706/
    94. KT. Tartuntatautilain väliakaisen 48 a §:n soveltaminen. https://www.kt.fi/sopimukset/ohjeet/sote/suoja-koronaa-vastaan-tartuntatautilaki-48a
    95. Our World in Data. Coronavirus (COVID-19) vaccinations. https://ourworldindata.org/covid-vaccinations
    96. Stöhr, K. The WHO global influenza program and its animal influenza network. Avian Diseases 2003, 47: 934-938. https://pubmed.ncbi.nlm.nih.gov/14575090/
    97. McLean, K. Goldin, S. Nannei, C. Sparrow, E. Torelli, G. The 2015 global production capacity of seasonal and pandemic influenza vaccine. Vaccine 2016, 34: 5410-5413. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357707/
    98. Sparrow, E. Wood, J. Chadwick, C. Newall, A. Torvaldsen, S. Moen, A. Torelli, G. Global production capacity of seasonal and pandemic influenza vaccines in 2019. Vaccine 2021, 39: 512-520. https://www.sciencedirect.com/science/article/pii/S0264410X20315851
    99. Seneff, S. Nigh, G. Kyriakopoulos, A. Mccullough, P. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes and microRNAs. (Preprint) https://www.researchgate.net/publication/357994624_Innate_Immune_Suppression_by_SARS-CoV-2_mRNA_Vaccinations_The_role_of_G-quadruplexes_exosomes_and_microRNAs
    100. Aldén, M. Falla, F. Yang, D. Barghouth, M. Luan, C. Rasmussen, M. De Marinis, Y. Intracellular reverse transcription of Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 in vitro in human liver cell line. Current Issues in Molecular Biology 2022, 44: 1115-1126. https://www.mdpi.com/1467-3045/44/3/73/htm
    101. Talouselämä. Euroopan lääkevirasto EMA: Toistuvat tehosterokotteet voivat heikentää immuunivastetta. https://www.talouselama.fi/uutiset/euroopan-laakevirasto-ema-toistuvat-tehosterokotteet-voivat-heikentaa-immuunivastetta/c8ebc022-da1c-4241-a865-821f9127f287
    102. Trumiyama, K. Miyazaki, Y. Shiozawa, S. Self-organized criticality theory of autoimmunity. PLoS One 2009, 4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795160/

    LÄHDE: MKRSUOMI.FI 05.03.2023